v3.24.1.u1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue:    
Total revenue $ 18 $ 286
Cost of revenue 57
Gross profit 18 229
Operating expenses:    
Research and development 5,092 5,821
General and administrative 23,077 21,380
Depreciation and amortization 361 293
Total operating expenses 28,530 27,494
Loss from operations (28,512) (27,265)
Other income (expense):    
Interest income, net 9 3
Other income (expense), net: (187)
Loss before income taxes (28,690) (27,262)
Income taxes (benefit)
Net loss (28,690) (27,262)
Non-controlling interest (351) 210
Net loss attributable to BioSig Technologies, Inc. (29,041) (27,052)
Preferred stock dividend (9) (9)
Preferred stock deemed dividend (210)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (29,050) $ (27,271)
Net loss per common share, basic $ (3.95) $ (6.33)
Net loss per common share, diluted $ (3.95) $ (6.33)
Weighted average number of common shares outstanding, basic 7,351,794 4,307,244
Weighted average number of common shares outstanding, diluted 7,351,794 4,307,244
Product [Member]    
Revenue:    
Total revenue $ 254
Service [Member]    
Revenue:    
Total revenue $ 18 $ 32

Source